BMET - Biomet $38.69 (+0.25)

Biomet's goal is to develop and market products that treat a variety of orthopedic problems. Their market has been growing as our population becomes older. Currently the Company has an impressive array of orthopedic surgical and rehabilitative tools. Some of these products include reconstructive and fixation devices, electrical bone growth stimulators, bone cements, general surgical supplies and dental implants. Last quarter, Biomet beat the consensus analysts estimate by a penny, with profits of $0.27 a share. The current quarter just ended and when Biomet reports its results on December 13th, it is expected that the Company will report profits of $0.29. Biomet trades with a P/E of 35.49. This year, investors have lost faith in the ability of technology stocks to maintain their growth rates. They have, instead, been making bets in companies like Biomet, which have more stable growth rates. At first glance, one would think that Biomet's share price is not high enough for a split announcement. However, we are right back in split range, as the Company did announce a 3:2 split in early July when the stock was trading at $38.00. The split was paid in early August. Friday was a particularly volatile day for Biomet. The stock came within a couple of points of our $33.00 stop but managed to rally and actually close above the previous day's high. This is called an outside day and it is typically bullish for a stock going forward. The 20-DMA should provide support just below $37.00. The MACD did turn negative on Thursday but in light of Friday's action, this signal could be false. The RSI has upside potential before the stock becomes overbought. OBV and Money Flow are both stable and much better than most stocks on the NASDAQ. If we are not stopped out, we will definitely exit this position if there is a split announcement or just before the earnings release. Please check our In Play area for stop ideas.

Picked on October 31st @ $36.19 Change since picked +2.50

CEFT - Concord EFS $44.00 (+2.81)

Concord EFS is a provider of ATM card and credit card authorization, processing, and electronic funds transfer services. The stock continues to move higher despite the recent turmoil in the market. On Friday, CEFT hit an intra-day high of $44.13 and closed slightly off its high, at $44. Shares of CEFT have posted gains in the last 4 sessions after bouncing off of major support at the 20-dma earlier in the week. Volume has been trending up, so CEFT may be ready to challenge its all-time high. As far a potential split announcement, the stock price is currently within historic split range and the company has enough shares to accommodate a split. CEFT has announced their last six 3:2 splits out of BoD meetings, so their next BoD seems like the most likely trigger event. From a technical standpoint, CEFT has support at Thursday's closing price of $42.88 with stronger support at $42.25, Friday's intra-day low. Resistance remains steady at $44.13 and then $46.13, Friday's intra-day high and also the all-time high. We are looking for entry points on a bounce off of $42.88 or a move above $44.13 on volume of at least 1 million shares by midday. We have moved our stops up to $42 to help protect a small gain.

Picked on October 31st @ $41.31 Change since picked +2.69

DHR - Danaher Corporation $63.88 (+2.81)

In two of the last three years, DHR was named to the Wall Street Journal's "Honor Roll" of companies, which ranks the top 20% of companies for greatest returns over a one, three, five, and ten year period. Over the last 10 years, DHR's shareholder returns grew at a compounded rate of 29%. This places the company #32 on the Fortune 500 list. We feel that strong returns over an extended period of time have a lot do to with the success of DHR's management team, which will certainly keep future prospects bright. In reference to the stock, DHR was held back from a breakout on Friday, as weakness across the market kept shares trading flat from the previous day. A quick intra-day advance to $64.94 reconfirmed stiff resistance at $65. An advance through this level will continue to be our initial gauge for a confirmed breakout. Should this scenario unfold, we'll look for DHR to be challenged further up at $70 (near all time high) and then $75. An extended run to these levels will likely need heavy buying to accompany the stock higher, so look for volume to meet or exceed 430 thousand shares. Keep in mind that an overbought reading on the Stochastic oscillator might also suggest that the stock could have a few more days of consolidation, prior to breaking out. With that said, we'll expect to see support arise at $63 (recent high) and further down at $62, bolstered by the 10-dma of $62.43. Set stops at $60 to protect against a potential reversal of the trend. Reconfirm positions with strength or weakness in the Dow Jones Industrial Average (INDU), prior to opening positions.

Picked on November 16th @ $63.50 Change since picked +0.38